Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q4 2019 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.35% and 1.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Misses Q4 Earnings Estimates

Late Thursday, Edwards reported adjusted income of $1.46 per share on $1.17 billion in revenue for its fourth quarter ended Dec. 31. EW stock rose modestly in after-hours action.

IBD 50 Stock Edwards Shrugs Off Mixed Quarter On Bullish Earnings Guide

AmerisourceBergen

Baxter

Thermo Fisher Scientific

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Jan 30 Earnings Roster: TMO, EW & More

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

Edwards Lifesciences stock tumbled Thursday after an analyst suggested sales of the company's heart-valve replacements, using a technique called TAVR, are experiencing a slowdown.

Leading Medtech Stock Hammered On Potential Slowdown In Heart Devices

Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.

Here's Why You Should Retain Edwards Lifesciences Stock Now

The medical device developer kept its growth engine humming along last year. It expects double-digit growth again in 2020.

Here's Why Edwards Lifesciences Stock Rose 52.3% in 2019

Danaher

SPDR Dow Jones Industrial Average ETF

General Electric

iShares Russell 2000 ETF

Invesco QQQ

SPDR S&P 500 ETF Trust

ProShares Ultra S&P 500

iPath S&P 500 VIX Short-Term Futures ETN Class A

Assessing Risk Levels In Equity Markets, With Michael Gettings (Podcast Transcript)

In the latest trading session, Edwards Lifesciences (EW) closed at $234.61, marking a -0.5% move from the previous day.

Edwards Lifesciences (EW) Stock Moves -0.5%: What You Should Know

Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.

Edwards (EW) Rides on Innovation Despite Regulatory Issues

Edwards Lifesciences (EW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Edwards Lifesciences (EW) Upgraded to Strong Buy: Here's Why

Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.

Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth

Bruker

Incyte

Inmode Ltd

Vertex Pharmaceuticals

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why You Should Keep An Eye On These 5 Leading Health Care Stocks

Align Technology

Globus Medical

LeMaitre Vascular

QuidelOrtho Corp

Repligen

ResMed

Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.

These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why

Edwards Lifesciences makes the world better for employees, patients, and communities. With its stock up 164% over the last three years, it has further to go.

Edwards Lifesciences Would Make Peter Drucker Smile

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Edwards Lifesciences (EW) Up 6.1% Since Last Earnings Report: Can It Continue?

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

ABIOMED

DexCom

Abiomed, DexCom, Quidel, Other Medical Equipment Stock Buys

Biogen

Celgene

DaVita

HCA Healthcare

Pfizer

Teleflex

Health Care Select Sector SPDR Fund

DENTSPLY SIRONA

These are the health care stocks with the best value, fastest growth, and most momentum for November.

Top Health Care Stocks for November 2019

Edwards Lifesciences (EW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Edwards Lifesciences (EW) Gain on Rising Earnings Estimates?

Edwards Lifesciences Is A Buy Taking Into Account Patent Dynamics

Edwards Lifesciences (EW) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for Edwards Lifesciences Stock (EW)